NeuMedics Overview
- Year Founded
-
2008
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
NeuMedics General Information
Description
Developer of eye drops intended to reduce inflammation and improve vision in patients with diabetic macular edema (DME). The company's product is a naphthacene carboxamide derivative formulated into an eye drop-based microemulsion that is self-administered to decrease inflammation by inhibiting pro-inflammatory compounds, activating or depleting specific phosphatases, and decreasing vascular permeability, enabling users over currently available therapies, such as the ability to be self-administered and the potential to reduce the risk of adverse events.
Contact Information
Website
kk2.665.myftpupload.comCorporate Office
- 5223 SouthWest Jacobsen Road
- Seattle, WA 98116
- United States
Corporate Office
- 5223 SouthWest Jacobsen Road
- Seattle, WA 98116
- United States
NeuMedics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Secondary Transaction - Private | 0000 | Completed | Generating Revenue | |||
| 2. Grant | 04-May-2015 | 00000 | 0000 | Completed | Generating Revenue | |
| 1. Angel (individual) | 05-May-2009 | $88K | $88K | Completed | Startup |
NeuMedics Patents
NeuMedics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20100009981-A1 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Active | 11-Jul-2008 | 0000000000 | 00 |
| CA-2730377-A1 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Active | 11-Jul-2008 | 0000000000 | |
| US-8338477-B2 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Active | 11-Jul-2008 | 0000000000 | 00 |
| US-20170144979-A1 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Active | 11-Jul-2008 | 0000000000 | |
| US-9896422-B2 | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits | Active | 11-Jul-2008 | C07D265/34 | 00 |
NeuMedics Executive Team (3)
| Name | Title | Board Seat |
|---|---|---|
| Iain Duncan | Co-Chief Executive Officer & Chief Operating Officer | |
| William Schwieterman MD | Chief Executive Officer |
NeuMedics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Washington State Life Sciences Discovery Fund | Government | 000 0000 | 000000 0 |
NeuMedics FAQs
-
When was NeuMedics founded?
NeuMedics was founded in 2008.
-
Who is the founder of NeuMedics?
Barbara Wirostko MD is the founder of NeuMedics.
-
Who is the CEO of NeuMedics?
Iain Duncan and William Schwieterman MD are the CEOs of NeuMedics.
-
Where is NeuMedics headquartered?
NeuMedics is headquartered in Seattle, WA.
-
What industry is NeuMedics in?
NeuMedics’s primary industry is Drug Delivery.
-
Is NeuMedics a private or public company?
NeuMedics is a Private company.
-
What is NeuMedics’s current revenue?
The current revenue for NeuMedics is 00000.
-
How much funding has NeuMedics raised over time?
NeuMedics has raised $88K.
-
Who are NeuMedics’s investors?
Washington State Life Sciences Discovery Fund has invested in NeuMedics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
